Published: Oct. 27, 2026 - 14:08:58 Ajou University-led team uncovers how CB1R receptor in macrophages worsens psoriatic skin inflammation South Korean researchers have identified a new molecular mechanism that drives the worsening of psoriasis, a chronic inflammatory skin disease. The team confirmed that suppressing the…
Johnson & Johnson (NYSE: JNJ) is seeing quick uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices. New independent physician research reports Icotyde prescriptions are building momentum and gaining share within the oral advanced therapy segment. Surveyed dermatologists indicate…
Vanda Pharmaceuticals CEO Mihael Polymeropoulos told Newsmax on Thursday that the company's recently approved motion sickness drug, Nereus, could help people taking popular GLP-1 medications manage nausea and vomiting, potentially allowing them to remain on treatment. On "Bianca Across the…
Written by Steve Bryson, PhD | Oct. 23, 2026 Treatment with melatonin and pioglitazone, two approved drugs that act on metabolism, improved motor function and prolonged survival in a mouse model of spinal muscular atrophy (SMA), with melatonin having the greater impact on…
Current European and UK guidance incorporates comorbidity assessment and, where appropriate, communication between dermatology and gastroenterology into treatment planning Plaque Psoriasis and Crohn’s Disease: Shared Biology, the IL-12/23 Pathway and Clinical Considerations Current European and UK guidance incorporates comorbidity assessment…
New WHO report: 100 million people affected by psoriasis, action needed to provide care, overcome discrimination. - Providing training for health professionals, especially in primary care settings; - Developing standardised guidelines for the diagnosis of psoriasis and its treatment; - Empowering people with psoriasis…
But psoriasis does not spread through touch, and people living with the condition pose no risk to those around them. The patches may be visible, but what causes them has little to do with an infection... A red, scaly patch…
Interested in Oruka Therapeutics, Inc.? Here are five stocks we like better. ORKA-001's 600-milligram regimen achieved a 61% PASI 100 complete-clearance rate and an 86% PASI 90 response rate at week 16 in the Phase IIb EVERLAST-B psoriasis study. Lower-dose regimens produced PASI 100 rates…
Oruka Therapeutics (ORKA) reported positive Phase 2b results showing that its experimental drug ORKA-001 demonstrated high rates of skin clearance in patients with moderate-to-severe plaque psoriasis, according to data from the EVERLAST-B study. At Week 16, patients receiving the high 600 mg dose…
With millions of Americans now taking GLP-1 medications, Eli Lilly says a new experimental drug could deliver more than double the weight loss seen with current treatments. Eli Lilly on Wednesday released Phase 3 trial results for retatrutide, an investigational drug…
Semaglutide and tirzepatide injections for weight loss: results, who uses them, supply and the GLP-1 boom.
An article joins this feed when it matches these terms. Each one is also a search of its own.